Evidence map›Paper›PMID 29804189›Full record

ArticleInflammation2018

Anti-inflammatory Effect of Somatostatin Analogue Octreotide on Rheumatoid Arthritis Synoviocytes.

Claudia Casnici, Donatella Lattuada, Katia Crotta, Marcello Claudio Truzzi, Costantino Corradini, Francesca Ingegnoli, Noemi Tonna, Fabio Bianco, Ornella Marelli

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Octreotide and direct/indirect lung injury.Research in pharmaceutical sciences · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Claudia CasniciFerdinando Santarelli Foundation, Corso Venezia 18, 20122, Milan, Italy. claudia.casnici@gmail.com.ORCID http://orcid.org/0000-0002-5478-0239
Donatella LattuadaDepartment of Medical Biotechnologies and Translational Medicine, School of Medicine, University of Milan, Via Vanvitelli 32, 20129, Milan, Italy.
Katia CrottaDepartment of Medical Biotechnologies and Translational Medicine, School of Medicine, University of Milan, Via Vanvitelli 32, 20129, Milan, Italy.
Marcello Claudio TruzziOrthopaedic Institute Gaetano Pini, Piazza A. Ferrari 1, 20122, Milan, Italy.
Costantino CorradiniDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, c/o 1st University Division of Orthopaedics and Traumatology, ASST Gaetano Pini, 20112, Milan, Italy.
Francesca IngegnoliDivision of Rheumatology, ASST Pini, Department of Clinical Sciences & Community Health, University of Milano, 20122, Milan, Italy.
Noemi TonnaNeuro-Zone srl, OpenZone, Via Ariosto 21, 20091, Bresso, MI, Italy.
Fabio BiancoFerdinando Santarelli Foundation, Corso Venezia 18, 20122, Milan, Italy.
Ornella MarelliDepartment of Medical Biotechnologies and Translational Medicine, School of Medicine, University of Milan, Via Vanvitelli 32, 20129, Milan, Italy.
University of Milan · ITPirelli (Italy) · ITIstituto Ortopedico Gaetano Pini · ITNeuro-Zone (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somatostatin and its analogues are known to have modulatory effects on immune response and their anti-proliferative, anti-angiogenic, and analgesic properties make them attractive candidates for a therapeutic use in immune-mediated diseases, such as rheumatoid arthritis. Here, we demonstrate the ability of the somatostatin analogue octreotide to inhibit interleukin-15 and to increase interleukin-10 production by rheumatoid arthritis fibroblast-like synovial cells maintained in a chronic inflammatory state. We also prove that the inhibitory effect of octreotide on interleukin-15 and tumor necrosis factor-α production depended on the increase in interleukin-10, since neutralizing anti-interleukin-10 antibody was able to partially reverse this inhibition. In addition, our observations suggest an octreotide control on purinergic signaling, with an inhibitory effect on purinergic P2X and P2Y receptors activation. This would have great implications, considering the roles of P2 receptors in the onset of inflammation. Data here reported extend knowledge on the biological action of octreotide and underline its multiple effects on immune response, which could make octreotide an attractive and valid support for the therapy of diseases where several inflammatory mediators are involved, such as rheumatoid arthritis, and in which the simultaneous action on different aspects can be a successful strategy.

Indexed as

Arthritis, RheumatoidHumansInflammationInterleukin-10Interleukin-15OctreotidePurinergic AgentsSomatostatinSynoviocytesTumor Necrosis Factor-alphaIL10 protein, humanInterleukin-10Interleukin-15OctreotidePurinergic AgentsSomatostatinTumor Necrosis Factor-alphacytokinesinflammationoctreotiderheumatoid arthritissomatostatin analoguessynoviocytes

Identifiers

PMID29804189
OpenAlexW2803365975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.